Compare Gilead Sciences, Inc. (GILD) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Philip Morris International Inc. — how do they compare? Gilead Sciences, Inc. trades at $136.02 (market cap $163.51B), while Philip Morris International Inc. trades at $188.83 (market cap $281.91B). The key difference: Philip Morris International Inc. is the larger of the two by market cap, and Philip Morris International Inc. pays the higher dividend (3.25%). Which is the better fit depends on your goals.
| GILD | PM | |
|---|---|---|
Market Cap | $163.51B | $281.91B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $191.86 |
52-Week Low | $108.22 | $144.33 |
Enterprise Value | $178.05B | $328.41B |
Dividend Yield | 2.49% | 3.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Philip Morris International (PM) trades at $175.95, down 2.35% amid a bearish technical signal and recent profit forecast revision. The company reported strong Q1 2026 EPS of $1.96, beating estimates, but faces headwinds from a $500 million impairment charge and margin pressures. Revenue growth remains steady, with 2025 revenue at $40.65 billion and net income margin of 26.74%. Analyst consensus is bullish with a $194 price target, though technical indicators show resistance near $179.
The stock presents a mixed outlook: solid fundamentals and high analyst buy ratings support upside potential, but near-term risks include cost pressures, currency volatility, and illicit market growth. Long-term investors may find value in the dividend and brand strength, while caution is warranted due to regulatory and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
